CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany.

AstraZeneca is an innovation-driven biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines that are innovative, effective, and which offer added benefits such as reduced side effects or better ways of taking the treatment. AstraZeneca focuses on getting the best from every medicine they make by exploring all the ways it can be used or improved. AstraZeneca was established on April 6, 1999, in Cambridgeshire, United Kingdom.

XenTech SAS operates as a biotech and clinical research company that specializes in preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. The firm also engages in therapeutic development in oncology through translational platform and developing clinically relevant tumor models. The company was founded by Jean-Gabriel Judde and Pascal Leuraud in 2006 and is headquartered in Evry, France.

KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies. Its 3DKUBE technology platform conveniently and cost-effectively incorporates perfusion flow, accommodates all scaffold materials, allows in situ imaging, models complex human biology using segregated cell co‐culture, and is a single-use disposable. 3DKUBE cell‐based assays leverage these features to create better in vitro prediction of complex biochemical responses in humans, with a focus on the evaluation of drug toxicity and efficacy prior to use in human clinical trials.

Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians and patients with high-value in vitro diagnostic oncology products.Veridex’s products will significantly benefit patients through earlier disease detection, and will enable personalized strategies to improve patient management and outcomes.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already been completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.

Cytovation AS is a Norwegian company located in Bergen. The firm develops and researches on dermatological diseases. It was founded by Per Eystein, Stein Christian Mohn and Rolf Bjerkvig. Lars Prestegarden is currently the CEO of the company.\nThe company says this about itself: Cytovation ASA is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class immunotherapy targeting the cell membrane of tumor cells. The company is a spin-off from the University of Bergen (Norway), the city where it is headquartered.

MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.

Taiho Pharmaceutical Co., Ltd. is engaged in the research, development, production, distribution, and marketing of pharmaceutical products. The company develops drugs primarily in the area of oncology. It also develops other pharmaceuticals, controlled medical devices, designated quasi-drugs, second-class OTC drugs, designated second-class OTC drugs, and third-class OTC drugs; S-1 for the treatment of gastric cancer; TAS-102 for the treatment of colorectal cancer; and anticancer agents for oncologists, other medical care professionals, and patients. In addition, it engages in the research and development in the areas of oncology,

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Robert Bosch GmbH engages in the development of the engineering and electronics sector. Its business sectors include; mobility solutions, industrial technology, consumer goods, and energy and building technology. The company was founded by Robert Bosch in 1886 and is headquartered in Gerlingen-Schillerhöhe, Germany.

Wuhan Shengrun Biotechnology Co., Ltd., established on 2018-04-17, Business scope includes biomedicine,medical instruments,food technology development,technology transfer,technical consulting;Class I and II medical devices,Wholesale and retail of food;Technology Development in Bioengineering,technical consulting,technology transfer;Engaged in technology development in the field of cell science,technical consulting,technology transfer;Cell Storage Technology Services(Does not include diagnosis and treatment);Health Advisory(Does not include diagnosis and treatment);development of cosmetics,Wholesale and retail;Import and export,Technology Import and Export,Agent import and export(Does not contain goods or technologies that are prohibited or restricted from import and export by the state).(Projects subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Zhejiang Cancer Hospital is a Chinese private company located in Hangzhou. The firm operates as an cancer hospital.